ClinicalTrials.gg
Active, not recruitingNCT07003919Updated Jul 22, 2026

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

A Phase 3 interventional study of DBV712 250 mcg and Placebo in Allergy and Peanut Allergy, sponsored by DBV Technologies. Active, not recruiting at 91 sites in 8 countries. Open to participants aged 1 Year to 3 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Primary conditionPeanut HypersensitivityRegistry: HypersensitivityReclassifiedWhy we changed it
Registry
Hypersensitivity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Peanut Hypersensitivity
Why
  1. The study's listed conditions name Peanut Hypersensitivity, a narrower term within Hypersensitivity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by DBV Technologies · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
1 Year to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.

Planned enrollment
3rd of 10
480 · median 105
Started
2025
the only one that year
Phase 3
4 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
5 of 10
DBV Technologies

Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 3, and was the 10th registered.

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

Browse Peanut Hypersensitivity studies →

Open to participants now

None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →

About palforzia

Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 1 Year to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing palforzia in Peanut Hypersensitivity as a file.
02

Study summary

The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.

Read the detailed description

This is a Phase 3 randomized double-blind, placebo-controlled (DBPC) study of 6-months duration to assess the safety of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE).

The overall maximum study duration for each participant will be approximately 112 weeks: Screening Period of 6-weeks, DBPC Treatment Period of 26-weeks, Open-label Period of 78-weeks and Follow-up Period of 2-weeks.

For participation eligibility, please refer to eligibility criteria section.

Randomization of eligible participants will occur in a 3:1 ratio to DBV712 250 mcg (active treatment) or placebo, respectively.

03

Conditions studied

  • Allergy
  • Peanut Allergy

Browse trials for

Keywords

  • Peanut hypersensitivity
  • Epicutaneous Immunotherapy (EPIT)
  • Epicutaneous
  • Immunotherapy
  • Viaskin
  • Nut and Peanut Hypersensitivity
  • Food Hypersensitivity
  • Peanut Allergy
  • Food Allergy
  • Nut and Peanut Allergy
  • Safety Study
04

In context

Peanut Hypersensitivity Reclassified

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

This study's planned enrollment of 480 is above the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.

Browse Peanut Hypersensitivity studies →

Lead sponsor

DBV Technologies is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Compared within Peanut Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Aged 1 through 3 years at Visit 1 (screening).
  • Physician-diagnosed peanut allergy and following a strict peanut-free diet
  • Peanut-specific IgE > 0.7 kUA/L.
  • A positive peanut SPT with the largest wheal diameter of ≥ 6 mm at Visit 1 (screening).
  • An ED ≤ 300 mg peanut protein at screening double-blind placebo-controlled food challenge (DBPCFC).

Key Exclusion Criteria:

  • Peanut allergic subjects presenting a medical history of severe anaphylaxis to peanut.
  • Severe generalized dermatologic disease involving the proposed treatment application area (interscapular region).
  • Current immunotherapy for any allergen (including food allergy, allergic rhinitis and/or insect allergy).
  • History of any immunotherapy for peanut allergy, including Epicutaneous immunotherapy (EPIT), oral immunotherapy (OIT), sublingual immunotherapy (SLIT).
  • Treatment with any monoclonal antibody or biologic immunomodulatory therapy within 6 months prior to Visit 1.
  • Uncontrolled persistent asthma.
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    DBPC Treatment Period: DBV712 250 mcg

    Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 6 months.

    Combination Product: DBV712 250 mcg

  • Placebo comparator
    DBPC Treatment Period: Placebo

    Participants will apply DBV712 matching placebo epicutaneous system (or patch), daily for a period of 6 months.

    Combination Product: Placebo

  • Experimental
    Optional Open-Label Extension-Period: DBV712 250 mcg

    The 6-month DBPC period will be followed by an optional open-label extension (OLE) period during which eligible participants will receive DBV712 250 mcg for a duration of 18 months (representing 24 months of active treatment for those participants initially randomized to DBV712 250 mcg and 18 months of active treatment for those participants that were initially randomized to placebo).

    Combination Product: DBV712 250 mcg

Interventions

  • Combination productDBV712 250 mcg

    DBV712 250 mcg epicutaneous system.

    Also known as: Viaskin® Peanut Patch

  • Combination productPlacebo

    DBV712 matching placebo epicutaneous system.

07

What researchers measure

Primary outcomes

  1. DBPC Treatment Period: Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)

    Time frame: Through DBPC Treatment Period, 6 months

Other outcomes

  1. Concentration of peanut-specific IgE (kUA/L) at baseline and month 6.

    Time frame: Month 6

  2. Concentration of peanut-specific IgG4 (mg/L) at baseline and month 6.

    Time frame: Month 6

  3. DBPC Treatment Period: Change from baseline in peanut Skin Prick Test (SPT) mean wheal diameters

    Time frame: Month 6

08

Study locations

91 sites
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

Of 15 phase 3 interventional studies under Peanut Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 42. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 4, 2025
StartActual
Jun 24, 2025
Primary completionEst.
Nov 2026
CompletionEst.
May 2028
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07003919
Lead sponsor
DBV Technologies
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Jun 24, 2025
Primary completion
Nov 2026 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palforzia

Start the discussion